This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hong, T.-M. Articles by Yang, P.-C. Search for Related Content PubMed PubMed Citation Articles by Hong, T.-M. Articles by Yang, P.-C.

Targeting Neuropilin 1 as an Antitumor Strategy in Lung Cancer

Authors' Affiliations: ¹ National Taiwan University Center for Genomic Medicine, College of Medicine, National Taiwan University, ² Institute of Biomedical Sciences, Academia Sinica, and ³ Department of Internal Medicine and ⁴ Medical Research, National Taiwan University Hospital, Taipei, Taiwan; and Institutes of ⁵ Oral Medicine and ⁶ Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan

Requests for reprints: Pan-Chyr Yang, Department of Internal Medicine, National Taiwan University Hospital, No. 7, Chung Shan South Road, Taipei, Taiwan. Phone: 886-2-2356-2905; Fax: 886-2-2358-2867; E-mail: pcyang{at}ntu.edu.tw.

Purpose: Neuropilin 1 (NRP1) is a mediator of lung branching and angiogenesis in embryonic development and angiogenesis in cancer. The role of NRP1 in cancer progression is not fully elucidated. We investigated the role of NRP1 in cancer invasion and tumor angiogenesis, its signaling pathways, prognostic significance, and therapeutic implications.

Experimental Design: Sixty patients with non–small cell lung cancer (NSCLC) were studied. NRP1 mRNA expression was measured using real-time quantitative reverse-transcription PCR. NRP1 and cancer cell invasion, angiogenesis, and signaling pathways were studied using NRP1 stimulation by vascular endothelial growth factor 165 (VEGF₁₆₅) and NRP1 inhibition by small interfering RNAs (siRNA), soluble NRP1 (sNRP1), and NRP1-inhibition peptides. The NRP1-inhibition peptides were identified using a phage display peptide library.

Results: NSCLC patients with high expression of NRP1 had shorter disease-free (P = 0.0162) and overall survival (P = 0.0164; log-rank test). Multivariate analyses showed NRP1 is an independent prognostic factor in overall (HR, 2.37, 95% CI = 1.15 to 4.9, P = 0.0196) and disease-free survival [hazard ratio (HR), 2.38; 95% confidence interval (95% CI), 1.15-4.91; P = 0.0195] of NSCLC patients. Knockdown of NRP1 suppressed cancer cell migration, invasion, filopodia formation, tumorigenesis, angiogenesis, and in vivo metastasis. NRP1 signaling pathways involved VEGF receptor 2 and phosphoinositide-3-kinase (PI3K) and Akt activation. Two potent synthetic anti-NRP1 peptides, DG1 and DG2, which block NRP1 signaling pathways and suppress tumorigenesis, cancer invasion, and angiogenesis, were identified.

Conclusions: NRP1 is a cancer invasion and angiogenesis enhancer. NRP1 expression is an independent predictor of cancer relapse and poor survival in NSCLC patients. NRP1 plays a critical role in tumorigenesis, cancer invasion, and angiogenesis through VEGF, PI3K, and Akt pathways. NRP1 may have potential as a new therapeutic target in NSCLC.

This article has been cited by other articles:

				Y. Glinka and G. J. Prud'homme Neuropilin-1 is a receptor for transforming growth factor {beta}-1, activates its latent form, and promotes regulatory T cell activity J. Leukoc. Biol., July 1, 2008; 84(1): 302 - 310. [Abstract] [Full Text] [PDF]

				M. J. Gray, G. Van Buren, N. A. Dallas, L. Xia, X. Wang, A. D. Yang, R. J. Somcio, Y. G. Lin, S. Lim, F. Fan, et al. Therapeutic Targeting of Neuropilin-2 on Colorectal Carcinoma Cells Implanted in the Murine Liver J Natl Cancer Inst, January 16, 2008; 100(2): 109 - 120. [Abstract] [Full Text] [PDF]